NCT03485729Phase 2Terminated

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Study sponsor: Jazz Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-01-19Actual
Enrollment · participants27Actual
Source updated2024-12-24Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview